कृपया अन्य खोज का प्रयास करें
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Darren S. Cline | 60 | 2021 | Independent Director |
Robert Baffi | - | - | Member of Technical Advisory Board |
Michael Sun | - | - | Member of Technical Advisory Board |
Thomas Civik | 55 | 2021 | Independent Director |
Freda C. Lewis-Hall | 69 | 2021 | Independent Director |
Jason J. Luke | - | - | Member of Clinical & Translational Medicine Advisory Board |
Virgil Bryan Lawlis | - | - | Member of Technical Advisory Board |
Anthony W. Tolcher | - | 2021 | Member of Clinical & Translational Medicine Advisory Board |
Christopher O’Donnell | 54 | 2021 | Member of Technical Advisory Board |
Morris Rosenberg | - | - | Chairperson of Technical Advisory Board |
Jakob Dupont | 59 | 2023 | Independent Director |
Rachel Wallach Humphrey | 63 | 2022 | Independent Director |
Elliott M. Levy | 66 | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Patricia LoRusso | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Giulio Draetta | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Glenn A. Miller | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Paul A. Bunn | - | 2023 | Member of Clinical & Translational Medicine Advisory Board |
Santhosh Palani | 40 | 2024 | Independent Director |
Lara S. Sullivan | - | 2019 | CEO, President & Director |
John L. Flavin | 53 | 2019 | Independent Chairman |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है